• E S Mayne, L Scott, B Semete, A Julsing, S Jugwanth, N Mampeule, A David, M P Gededzha, A Goga, D Hardie, W Preiser, K Chetty, H Rees, I Sanne, K Mlisana, J A George, and W Stevens.
• Department of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; National Health Laboratory Service, Johannesburg, South Africa. elizabeth.mayne@nhls.ac.za.
• S. Afr. Med. J. 2020 Jul 17; 110 (9): 842-845.

AbstractAntibody tests for the novel coronavirus, SARS-CoV2, have been developed both as rapid diagnostic assays and for high-throughput formal serology platforms. Although these tests may be a useful adjunct to a diagnostic strategy, they have a number of limitations. Because of the antibody and viral dynamics of the coronavirus, their sensitivity can be variable, especially at early time points after symptom onset. Additional data are required on the performance of the tests in the South African population, especially with regard to development and persistence of antibody responses and whether antibodies are protective against reinfection. These tests may, however, be useful in guiding the public health response, providing data for research (including seroprevalence surveys and vaccine initiatives) and development of therapeutic strategies.

42 keywords...

hide…